GlassScriptPhysician profile
Melissa Bishop
NPI 1497112296
$3,824.70
in general payments reported to CMS, 2019-2025
38 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,169 · 2022: $734 · 2023: $789 · 2024: $935 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.53 |
| Education | $298.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,191.88 | 2021-2024 | Tagrisso, Lynparza, Enhertu |
| Gilead Sciences, INC. | $303.86 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $212.85 | 2021-2024 | Enhertu, Injectafer, Vanflyta |
| Lilly USA, LLC | $210.68 | 2021 | |
| Astellas Pharma US INC | $183.84 | 2021-2024 | Xospata |
| Janssen Biotech, INC. | $176.24 | 2021-2024 | Tecvayli, Darzalex, Talvey |
| Ipsen Biopharmaceuticals, INC | $118.84 | 2021-2024 | Onivyde, Somatuline Depot |
| Seagen INC. | $118.66 | 2023 | Adcetris |
| Janssen Pharmaceuticals, INC | $106.07 | 2022-2023 | Xarelto |
| Exelixis INC. | $99.00 | 2024 | |
| Merck Sharp & Dohme LLC | $92.98 | 2021-2024 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $91.83 | 2021-2022 | |
| Beigene USA, INC. | $72.60 | 2021-2023 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $70.16 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $59.51 | 2023-2024 | Monoferric, Cosela |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.